Drug intelligence / Profile preview

PHV02

Development stage
Phase 1
Lead developer
Public Health Vaccines
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

PHV02 is a live, recombinant vaccine candidate designed to protect against Nipah virus infection. It utilizes a vesicular stomatitis virus (VSV) vector in which the gene for the VSV glycoprotein is replaced by the Zaire ebolavirus glycoprotein (EBOV GP), and additionally expresses the Nipah virus (NiV) attachment glycoprotein G. This chimeric construction enables the vaccine to induce an immune response targeting both Ebola and Nipah viruses, with neutralizing antibodies against NiV considered a key mediator of protection. The vaccine is administered as an intramuscular injection and has demonstrated rapid onset of protective immunity in animal models. PHV02 is currently in Phase 1 clinical trials for Henipavirus infections, including Nipah virus infection[2][4][5][7].

Other names
rVSV-Nipah Virus Vaccine Candidate PHV02
02

Targets

Zaire ebolavirus glycoproteinNiV-G (Nipah virus attachment glycoprotein)

Beyond the preview

Go deeper on PHV02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHV02.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call